Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazharuddin, Anam A., Whyte, Andrew T., Gombos, Dan S., Patel, Nimisha, Razmandi, Azadeh, Chaudhry, Amina L., Al-Zubidi, Nagham S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Innovative Healthcare Institute 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714419/
https://www.ncbi.nlm.nih.gov/pubmed/36483585
http://dx.doi.org/10.36401/JIPO-22-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714419/
https://www.ncbi.nlm.nih.gov/pubmed/36483585
http://dx.doi.org/10.36401/JIPO-22-14

Ejemplares similares